Clinicians should consider incorporating sodium-glucose cotransport 2 inhibitors into the management of acute kidney disease and type 2 diabetes, according to investigators. Sodium-glucose cotransport ...

Credit: Getty Images. Despite a warning from the FDA Adverse Event Reporting System, studies have found that SGLT2 inhibitor use is not associated with an increased risk of AKI. Using a sodium-glucose ...

WASHINGTON – Results from new analyses further fleshed out the potent effect by the investigational SGLT1&2 inhibitor sotagliflozin on major cardiovascular adverse events in patients with type 2 ...

- Validates therapeutic benefit of combination approaches for a large segment of NASH patients- Demonstrates additive efficacy results and favorable tolerability profile SAN DIEGO, Nov. 02, 2021 ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio There was no significant difference in ...

Share on Pinterest Researchers say many people with type 2 diabetes aren’t getting the treatment they need. Kobus Louw/Getty Images Researchers report that 80% of U.S. adults with type 2 diabetes aren ...

ATLANTA, GA — A multicenter controlled trial testing the ability of an aldose reductase inhibitor to stabilize early-stage asymptomatic diabetic cardiomyopathy missed its primary endpoint, researchers ...

THE WOODLANDS, Texas, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced that a post-hoc analysis (“Efficacy of Sotagliflozin Among Older Adults: A Pooled ...